Last reviewed · How we verify
Sinovial
Sinovial is a Small molecule drug developed by Marcin Domżalski. It is currently in Phase 2 development.
Sinovial is a treatment being studied for various conditions, including osteoarthritis of the knee, osteoarthritis of the thumb, tennis elbow, and knee osteoarthritis. It is being tested as a single injection, with some studies comparing it to Triamcinolone Acetonide.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sinovial |
|---|---|
| Sponsor | Marcin Domżalski |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2) (NA)
- Efficacy and Safety of Sinovial®HL Single Injection in the Knee Osteoarthritis
- Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease (NA)
- A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee Osteoarthritis (PHASE3)
- Intra-articular Oxygen-ozone Therapy for the Treatment of Knee Osteoarthritis Compared With Hyaluronic Acid (PHASE3)
- Hyaluronate Injection for Lateral Epicondylitis (PHASE3)
- Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
- Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinovial CI brief — competitive landscape report
- Sinovial updates RSS · CI watch RSS
- Marcin Domżalski portfolio CI
Frequently asked questions about Sinovial
What is Sinovial?
Who makes Sinovial?
What development phase is Sinovial in?
Related
- Manufacturer: Marcin Domżalski — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing